Observations that make me uncomfortable, page-12

Totally agree, just putting out there what a recent research paper is dictating the "competition" launching in the next 12 months against the standard drugs, so people are not blind sighted thinking that we are the only drug launching the next 12 months.

As you have quite rightly pointed out, its important that everyone looks at each and every one of these "competitors" and understand the differences that ACL brings to the table, IMO - we have a very superior product for 2nd-3rd line treatment based on each of these companies.

As always DYOR.